Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Colorectal Cancer
What regimen would you offer a young fit patient with low grade mucinous adenocarcinoma of the appendix with pseudomyxoma peritonei to attempt to get him to cytoreductive surgery with HIPEC?
Related Questions
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
How would you approach a stage II colon cancer with negative ctDNA but markedly elevated CEA level post-colectomy?
What is your preferred third-line therapy for metastatic colon cancer, RAS-WT, MSS, low TMB with no targetable alterations?
What grade 3 toxicities would you expect sufficient overlap between capecitabine and 5-fluorouracil that you would avoid substituting one over the other?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
Would you ever consider foregoing surveillance CT scans for resected stage II or III colon cancer in favor of circulating ctDNA assays?
How was treatment response assessed on the PROSPECT trial?
Do you offer adjuvant chemotherapy to patients with rectal cancer who were on Watch-and-Wait, had local recurrence and underwent resection?
Would you offer chemotherapy to an elderly patient with MSI-H stage 3 colon cancer who cannot tolerate oxaliplatin?
